Abstract-Contrary to previous reports, recent enzymatic assays showed the predominance of chymase-like activity in rat arteries. We determined the existence and significance of such alternative pathways in rat carotid arteries by measuring contraction of arterial rings in organ baths and blood pressure in conscious rats. Hamster aorta served as a positive control for chymase. Temocapril (30 mol/L) inhibited the contractions to angiotensin (Ang) I (10 Ϫ9 to 10 Ϫ5 mol/L) except at high concentrations of Ang I (Ͼ10 Ϫ7 mol/L). Addition of chymostatin (100 mol/L) to temocapril exerted a synergistic inhibitory effect. Hamster aorta gave similar results, except that temocapril was 30-fold less effective than in rat arteries. Key Words: angiotensin-converting enzyme Ⅲ chymase Ⅲ aorta Ⅲ carotid arteries Ⅲ hamster S pecies differences exist in local angiotensin (Ang) IIforming pathways in the cardiovascular system mainly due to different characteristics of chymase. 1-3 Human and hamster chymases effectively cleave Ang I to form Ang II, 4,5 whereas rat chymase is Ang II-degrading. 6 It is therefore generally believed that rat arteries do not have any alternative pathway other than an angiotensin-converting enzyme (ACE)-mediated pathway. 3 This notion is supported by many reports indicating the equal effectiveness of ACE inhibitors and Ang II subtype 1 (AT 1 ) receptor antagonists in rat models of cardiovascular disease. These inhibitors similarly lowered blood pressure and prevented cardiovascular remodeling in spontaneously hypertensive rats 7 and TGR(mREN2)27 transgenic rats. 8 Recently, however, some investigators reported the presence of chymase-like activity in the homogenates of rat heart and aorta. 1,2 In particular, Akasu et al 2 even showed that chymase-like enzyme, rather than ACE, is the major Ang II-forming enzyme in the rat cardiovascular system in vitro. Despite such elegant biochemical observations, however, there is little physiological evidence supporting the notion that chymase-like enzyme plays such a significant role in rat vasculature. The unavailability of a chymase-specific inhibitor has hampered the clarification of pathophysiological roles of chymase. To circumvent this problem, a chymase-specific substrate, [Pro 11 ,D-Ala 12 ]Ang I, was developed. 9,10 This synthetic peptide has been used to show chymase-dependent Ang II formation in various species such as humans, 9,11 baboons, 12 hamsters, 13 marmosets, 14 and dogs, 15 but not in rats.
S pecies differences exist in local angiotensin (Ang) IIforming pathways in the cardiovascular system mainly due to different characteristics of chymase. [1] [2] [3] Human and hamster chymases effectively cleave Ang I to form Ang II, 4, 5 whereas rat chymase is Ang II-degrading. 6 It is therefore generally believed that rat arteries do not have any alternative pathway other than an angiotensin-converting enzyme (ACE)-mediated pathway. 3 This notion is supported by many reports indicating the equal effectiveness of ACE inhibitors and Ang II subtype 1 (AT 1 ) receptor antagonists in rat models of cardiovascular disease. These inhibitors similarly lowered blood pressure and prevented cardiovascular remodeling in spontaneously hypertensive rats 7 and TGR(mREN2)27 transgenic rats. 8 Recently, however, some investigators reported the presence of chymase-like activity in the homogenates of rat heart and aorta. 1, 2 In particular, Akasu et al 2 even showed that chymase-like enzyme, rather than ACE, is the major Ang II-forming enzyme in the rat cardiovascular system in vitro. Despite such elegant biochemical observations, however, there is little physiological evidence supporting the notion that chymase-like enzyme plays such a significant role in rat vasculature. The unavailability of a chymase-specific inhibitor has hampered the clarification of pathophysiological roles of chymase. To circumvent this problem, a chymase-specific substrate, [Pro 11 ,D-Ala 12 ]Ang I, was developed. 9, 10 This synthetic peptide has been used to show chymase-dependent Ang II formation in various species such as humans, 9, 11 baboons, 12 hamsters, 13 marmosets, 14 and dogs, 15 but not in rats.
The aims of this study were to determine functionally (1) whether the alternative Ang II-forming pathway exists in rat arteries and (2) whether it plays as significant a role as suggested by biochemical data. We compared the contractile responses to Ang I and [Pro 11 ,D-Ala 12 ]Ang I with and without ACE inhibitors (captopril and temocapril), an AT 1 receptor antagonist (CV 11974), or a serine protease inhibitor (chymostatin) in rat and hamster arteries. On the basis of the different characteristics of hamster and rat chymases, 4, 6 we used hamster aorta as a positive control for chymasedependent Ang II formation. 13 Our study demonstrates the presence of the alternative pathway in rat arteries. However, contrary to the biochemical observations, functionally the non-ACE pathway does not play a major role in rat vasculature either in vitro or in vivo.
Methods

Animals
Male Syrian hamsters (nϭ14, 155Ϯ4 g) and Wistar-Kyoto/Izm rats (nϭ40, 397Ϯ5 g) were obtained from Japan SLC (Shizuoka, Japan) and the Disease Model Cooperative Research Association (Kyoto, Japan), respectively. They were kept in a quiet room at constant temperature (20°C to 22°C) and under a 12:12-hour light-dark cycle. The experiments were performed in accordance with the institutional guidelines of the Osaka Medical College for the use of experimental animals.
Contraction Studies in Rat and Hamster Arteries
Under chloral hydrate anesthesia (350 mg/kg IP), animals were killed by exsanguination. The thoracic aorta of hamsters and the carotid arteries of rats were rapidly removed and cut into 2-mm-long rings under a microscope. We did not use rat aorta because of weak and variable responses and marked tachyphylaxis to Ang II, which precluded a construction of cumulative concentration-response curves. Instead, we compared rat carotid arteries with hamster aorta because both are conductance vessels with a similar size and similar dose-dependent responses to Ang II. Four rings with intact endothelium were mounted simultaneously in a Mulvany myograph (model 610 mol/L, JP Trading) filled with physiological salt solution (5 mL) of the following composition (mmol/L): NaCl 119.0, NaHCO 3 Ϫ5 mol/L) in a cumulative fashion. The concentrations of these substrates were selected to achieve similar contractile responses. 13, 14 Ring preparations that did not receive any antagonist(s) but only vehicle set up in parallel served as controls. We added 100 mol/L N G -nitro-L-arginine methyl ester (L-NAME) and 10 mol/L indomethacin in all baths to avoid a possible difference in basal release of nitric oxide in the arteries and to exclude a possible effect of ACE inhibitors on the kinin-prostaglandin system. 3, 13, 16 In a separate set of rings, we determined the time to the onset of response and the time to reach the peak of tension by incubating the rings with either Ang I (10 
Blood Pressure Measurement in Conscious Rats
Under anesthesia with 4% chloral hydrate (350 mg/kg), catheters (PE 50) were inserted into the right carotid artery and jugular vein of rats and were exteriorized in the interscapular area. The catheters were filled with heparinized saline (10 IU/mL), and the rats were allowed to recover overnight. The carotid catheter was connected to a micromanometer (PC350, Millar Instruments) to record blood pressure continuously with the computerized system using MacLab software. After a 30-minute stabilization period, Ang I (0.03 to 30 g/kg) or [Pro 11 ,D-Ala 12 ]Ang I (7 to 700 g/kg) was administered via the jugular catheter to achieve comparable pressor responses. 13, 14 On a separate day, after a 30-minute incubation with temocapril (2 mg/kg) or CV 11974 (1 mg/kg), the dose-dependent responses to the peptides were compared. Blood pressure measurement was not done in hamsters because it has already been reported with the same protocol. 13 
Pharmacological Agents
Chymostatin, phenylephrine, L-NAME, indomethacin, and Ang I were purchased from Sigma Chemical Co. [Pro 11 ,D-Ala 12 ]Ang I was synthesized at the Peptide Institute. CV 11974 was a gift of Takeda Chemical Industries (Osaka, Japan). Temocapril and captopril were supplied by Sankyo Pharmaceutical. Chymostatin was first dissolved in dimethyl sulfoxide and then diluted in the solution in baths so that the final dimethyl sulfoxide concentration was 0.1%. This concentration of dimethyl sulfoxide was added to each bath to exclude any effect on the contractile responses. All drugs were diluted in the physiological salt solution and expressed as final molar concentrations in the organ baths.
Statistics
The contractile responses of the isolated arterial rings were expressed as percentage of contraction induced by 10 mol/L phenylephrine. The negative log molar value (pD 2 ) of the concentration at 50% of the maximum contraction (ED max ) was calculated from the fits of each separate curve. Statistical evaluation was done by Student's t test for paired and unpaired observations. In the isolated vessel study, n denotes the number of experiments, and in the experiments in vivo, n equals the number of animals studied. Values are expressed as meanϮSEM. A value of PϽ0.05 was considered statistically significant. Figure 1A shows dose-dependent contractile responses to Ang I in rat carotid arteries (nϭ16) in the presence and absence of various inhibitors. Temocapril completely suppressed the contractions except at very high concentrations of Ang I (Ͼ10 Ϫ7 mol/L), shifting the pD 2 from 7.34Ϯ0.11 to 6.12Ϯ0.08 (PϽ0.001, nϭ12). Ang I concentration needed for the onset of contraction was shifted from 10 nmol/L to 3 mol/L in the presence of temocapril, indicating that a 300-fold higher dose of Ang I was necessary to yield the first response. In contrast, chymostatin had no effect on the Ang I-induced contraction ( Figure 1A, nϭ7) , indicating the predominance of the ACE pathway in rat arteries. However, when chymostatin was combined with temocapril, there was To compare the functional contribution of different characteristics of chymases to vascular Ang II formation, the same protocol was repeated in hamster aorta. Temocapril significantly inhibited the contractions to Ang I, shifting pD 2 from 7.63Ϯ0.12 to 6.38Ϯ0.08 (PϽ0.001) without affecting the ED max (Figure 2A, nϭ12) . Compared with rat arteries, however, temocapril was 30-fold less potent in hamster arteries, because a 10-fold higher concentration of Ang I (from 30 to 300 nmol/L) was needed to elicit the first response ( Figure  2A) , whereas a 300-fold higher Ang I dose was required in rat arteries ( Figure 1A) . Chymostatin had no effect on Ang I-induced contraction (Figure 2A, nϭ7) , suggesting that even in hamster arteries, the alternative pathway is not a main pathway. The addition of chymostatin to temocapril shifted the dose-response curve to the right (pD 2 6.38Ϯ0.10 to 5.92Ϯ0.09, PϽ0.05, nϭ11). The synergistic inhibitory effect was similar in hamster and rat arteries, requiring 3 times higher doses of Ang I to elicit the first response in each vessel. CV 11974 significantly suppressed the responses to Ang I (PϽ0.001, Figure 2A, nϭ8) .
Results
Responses to Ang I and [Pro 11 ,D-Ala 12 ]Ang I in the Carotid Arteries of Rats
[Pro 11 ,D-Ala 12 ]Ang I induced dose-dependent responses similar to those induced by Ang I (ED max 77Ϯ10% versus 78Ϯ11% with Ang I, Pϭ0.85, Figure 2B, nϭ16) . In contrast to Ang I, the inhibitory effects of various inhibitors on the responses to [Pro 11 ,D-Ala 12 ]Ang I were similar in hamster and rat arteries. As shown in Figure 2B , chymostatin shifted pD 2 from 6.58Ϯ0.09 to 6.04Ϯ0.08, PϽ0.05, without affecting the ED max (nϭ11). Although temocapril did not affect the responses (nϭ7), CV 11974 inhibited them significantly (PϽ0.001, Figure 2B , nϭ8). As with rat arteries, the addition of temocapril to chymostatin exerted no synergistic effect (pD 2 To rule out the possibility that the inhibitory effects on Ang I-induced contraction we obtained are specific for temocapril, we also evaluated the effect of captopril (100 mol/L) in rat and hamster arteries (nϭ8 each). We found no significant differences in the inhibitory effects of these ACE inhibitors in our experimental settings (captopril data not shown).
Time to the Onset of Response and to Reach the Peak of Tension
In another set of rat and hamster arteries (nϭ10 each), we compared the time course of contractile responses to each peptide. Ang I (10 Ϫ6 
]Ang I in Conscious Rats
To determine the contribution of the alternative pathway observed in the isolated rat arteries to the in vivo Ang II formation, we compared pressor responses to both peptides and the inhibitory effects of temocapril and CV 11974 in conscious rats (nϭ28). Baseline mean arterial pressure was 100Ϯ4 mm Hg, and heart rate was 312Ϯ11 bpm. Neither temocapril nor CV 11974 affected baseline blood pressure or heart rate (data not shown). Figure 3A and 3B, nϭ14 each), confirming the results obtained in in vitro experiments. In contrast to the findings in the isolated arteries, however, temocapril completely suppressed the Ang I-induced responses even at high concentrations of the peptide, as did CV 11974 ( Figure 3A , nϭ7 each), suggesting that the non-ACE pathway found in vitro does not play a role in vivo. As found in the isolated arteries, CV 11974, but not temocapril, abolished the responses to [Pro 11 ,D-Ala 12 ]Ang I ( Figure 3B , nϭ7 each), indicating that the pressor responses to the synthetic peptide were mediated by enzyme(s) other than ACE. Chymostatin could not be used in vivo because dimethyl sulfoxide, in which chymostatin was dissolved, is toxic to animals.
Discussion
Recent enzymatic data showed the predominance of non-ACE pathway in rat arteries, 2 whereas previous functional data denied even the existence of such a pathway in rat vasculature. 3 The present study clarified these discrepancies by addressing the questions of (1) whether the alternative pathway exists in rat arteries and (2) whether such a non-ACE pathway has physiological significance. Our study demonstrated the existence of an ACE-independent Ang II-forming pathway in rat carotid arteries, as evidenced by a greater inhibitory effect of CV 11974 and the combination of chymostatin and temocapril compared with temocapril alone on Ang I-induced contraction. The vasoconstrictive responses to [Pro 11 ,D-Ala 12 ]Ang I, which were not affected by temocapril, further confirmed the presence of the alternative pathway in rat arteries.
In contrast to the present results, Okunishi et al 3 failed to show any additive inhibitory effect of combining captopril and chymostatin on responses to Ang I in rat arteries, thus denying the presence of the alternative pathway in rats. The discrepancy is probably because the concentration of Ang I used in their study was too low (10 Ϫ7 mol/L). At this concentration, we also found that captopril or temocapril almost completely suppressed the Ang I-induced contraction in rat arteries. Consistent with our data, the synergistic inhibitory effect of captopril and chymostatin was also reported in the perfused rat hindlimb. 17 Thus, the predominance of the ACE or non-ACE pathway appears to be highly dependent on the concentrations of Ang I used. Most investigators used only an extremely high concentration of Ang I (10 Ϫ6 mol/L) to show the importance of chymase-dependent Ang II formation in human 11 and dog 14 arteries and human detrusor muscle. 18 However, if one uses only such an unphysiologically high concentration of Ang I, even in rat arteries the alternative pathway predominates over the ACE pathway ( Figure 1A) .
The inhibitory effect of ACE inhibitors in our study was mainly due to the blockade of the renin-angiotensin system, because we used L-NAME and indomethacin to exclude a possible effect of ACE inhibitors on the kinin-prostaglandin system. In rat arteries, temocapril completely suppressed the responses to submaximal concentrations of Ang I, so that as much as a 300-fold higher dose of Ang I was necessary to yield a first contractile response to Ang I in the presence of temocapril. This is in contrast to human 16 and hamster arteries, which required 3-fold and 10-fold higher Ang I concentrations, respectively, to elicit the first response. These findings indicate that in rat arteries, the ACE pathway plays a greater role than in human vessels. In further support of this view, chymostatin had no effect on Ang I-induced contraction in rat arteries, a finding in contrast to human arteries. 3, 11, 16 Moreover, the non-ACE pathway in rat vessels was detected only when the concentrations of Ang I were extremely high. However, it is unlikely that the blood vessels are exposed to such high concentrations of Ang I in vivo, because plasma Ang I levels are relatively low. 19, 20 This can explain why there was no difference in the inhibitory effects of temocapril and CV 11974 on Ang I-induced pressor responses in our conscious rats. This interpretation is further supported by the equal effectiveness of ACE inhibitors and AT 1 receptor antagonists in hypertensive rats. 7, 8 In TGR(mREN2)27 transgenic rats, a hypertension model with the increased tissue renin-angiotensin system, quinapril and losartan equally prevented cardiac and vascular hypertrophy. 8 These findings suggest that even at the tissue level, the alternative pathway does not play a significant role in rats. However, we cannot exclude the 12 ]Ang I simply mean the presence of the ACE-independent pathway. The functional significance of the chymase-dependent pathway should also be determined with several concentrations of Ang I. To elucidate this issue, however, one should develop a chymase-specific inhibitor.
There are discrepancies in biochemical and functional evidence regarding the predominance of ACE versus chymase in various tissues. Although biochemical data showed the predominance of chymase-like activity in dog heart, 24 human detrusor muscle, 18 and rat and hamster aorta, 2,13 the functional results showed the predominance of ACE pathway in each tissue. 13, 18, 24 Thus, the biochemical data may overestimate the chymase-like activity, as suggested by Balcells et al. 1 Several reasons can be postulated to explain a possible overestimation. First, in the biochemical studies, extremely high concentrations of Ang I were used (in the range of 10 Ϫ4 mol/L), 1,2,13,18 which is not physiological. 2 Second, chymase is normally stored in the secretory granules of mast cells and must be actively secreted into the interstitium to exert its action. 22 However, in the process of tissue homogenization, large quantities of intracellular Ang II-forming enzymes, including chymase, would gain free access to a high concentration of Ang I. Other interesting biochemical and functional discrepancies are that (1) even though chymase-like activity predominated equally over ACE activity in the homogenates of human and rat arteries, 2 the present and previous functional observations 3,16 revealed a marked difference in the Ang IIforming pathways in rat and human vessels and (2) although biochemically, chymase-like enzyme-dependent Ang II formation was severalfold higher in hamster than in human arteries, 2 functional studies by us and others 13, 16 gave results opposite to the biochemical data. Together, these findings suggest that the biochemical results do not apply to the in vivo system. 25 We emphasize a need for a combined functional and biochemical approach. 24 Recently, Hollenberg et al 25 clearly showed the contribution of ACE-independent pathways in humans in vivo by using various classes of agents that block several enzymes in the renin-angiotensin system.
In summary, our in vitro study showed the presence of the alternative pathway mediated partly by chymostatin-sensitive enzyme(s) in rat arteries. However, contrary to the biochemical data, its functional contribution to Ang II formation in rat vasculature appears to be negligible, as substantiated by our in vivo results. 
